Peroxisome Proliferator-Activated Receptor γ: Implications for Cardiovascular Disease
Open Access
- 1 February 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 43 (2) , 297-305
- https://doi.org/10.1161/01.hyp.0000113626.76571.5b
Abstract
Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. PPARγ is expressed by macrophages, endothelial cells, and vascular smooth muscle cells. It regulates gene expression of key proteins involved in lipid metabolism, vascular inflammation, and proliferation contributing to atherogenesis and postangioplasty restenosis. The discovery of synthetic ligands for PPARγ has led to significant enhancement of our understanding of the mechanism of their ligand-dependent activation and subsequent biological effects, particularly with respect to the role of PPARγ in vascular pathophysiology. The thiazolidinedione PPARγ agonists not only improve insulin resistance in patients with type II diabetes but also exert a broad spectrum of antiatherogenic effects in vitro and in animal models of atherosclerosis. In this review, we summarize the important role of PPARγ as a molecular target for thiazolidinediones and its implications for the control of vascular inflammation and proliferation for the cardiovascular system.Keywords
This publication has 113 references indexed in Scilit:
- Peroxisome Proliferator-Activated ReceptorsHypertension, 2003
- Cloning of adiponectin receptors that mediate antidiabetic metabolic effectsNature, 2003
- PPAR activators inhibit endothelial cell migration by targeting AktBiochemical and Biophysical Research Communications, 2002
- Peroxisome Proliferator–Activated Receptor-γ Ligands Inhibit Nuclear but Not Cytosolic Extracellular Signal–Regulated Kinase/Mitogen–Activated Protein Kinase–Regulated Steps in Vascular Smooth Muscle Cell MigrationJournal of Cardiovascular Pharmacology, 2001
- Plasma leptin is independently associated with the intima-media thickness of the common carotid arteryInternational Journal of Obesity, 2001
- PPARγ and the Treatment of Insulin ResistanceTrends in Endocrinology & Metabolism, 2000
- Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non–insulin dependent diabetes mellitusJournal of the American College of Cardiology, 2000
- Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.Journal of Clinical Investigation, 1995
- Effects of pioglitazone on calcium channels in vascular smooth muscle.Hypertension, 1994
- Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin ResistanceScience, 1993